Spero Therapeutics SPRO
NASDAQ SPRO
$1.17 -0.05 (-3.67%)
As of: Oct 21, 2026 · 3:45 PM EDT

Spero Therapeutics (SPRO) EV to EBIT (2023 - 2026)

Updated

Spero Therapeutics' EV to EBIT was 12.90 in Q2 2026, up 119.6% from the prior quarter.

Analysis

Spero Therapeutics (SPRO) EV to EBIT (2023 - 2026) Analysis & Trends

On a trailing twelve-month basis, Spero Therapeutics' EV to EBIT was -11.17 through Jun 30, 2026; for FY2025, it came in at 14.44.

  • In earlier years, EV to EBIT was 0.07 in FY2023.
  • Quarterly EV to EBIT has moved between 0.07 (Q4 2023) and 14.44 (Q4 2025) over five years.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,138.33 Bn 1,106.91 Bn 19.71 Bn
2 Johnson & Johnson 618.82 Bn 537.35 Bn 17.26 Bn
3 AbbVie 503.36 Bn 476.47 Bn 12.70 Bn
4 Merck 369.59 Bn 323.96 Bn 12.21 Bn
5 Novartis Ag 298.57 Bn 262.56 Bn 11.24 Bn
6 Astrazeneca 261.25 Bn 234.94 Bn 12.86 Bn
7 Amgen 237.35 Bn 192.75 Bn 7.24 Bn
8 Gilead Sciences 191.27 Bn 165.47 Bn 6.22 Bn
9 Pfizer 170.03 Bn 116.68 Bn 10.94 Bn
10 Spero Therapeutics 68.11 Mn -127.67 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 12.90
Mar 31, 2026 5.87
Dec 31, 2025 14.44
Jun 30, 2024 0.43
Mar 31, 2024 0.48
Dec 31, 2023 0.07
API Access

Spero Therapeutics EV to EBIT API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ev-to-ebit&ticker=SPRO&period=max&api_key=YOUR_API_KEY